A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: MRG002|DRUG: Trastuzumab Emtansine for Injection
Sponsor: Shanghai Miracogen Inc.